Search

Displaying results 6181 - 6190 of 10000 in total
  1. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection.

  2. Drug

    GTI-2501

    go.drugbank.com/drugs/DB05406
    Experimental

    The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer. … Initial testing has demonstrated strong antitumor activity in preclinical studies in prostate cancer and a variety of other tumor types.

  3. Drug

    Desidustat

    go.drugbank.com/drugs/DB16135
    Investigational

    Desidustat is under investigation in clinical trial NCT04012957 (Desidustat in the Treatment of Anemia in CKD).

  4. Drug

    Demcizumab

    go.drugbank.com/drugs/DB12734
    Investigational

    Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.

  5. Drug

    Fenticonazole

    go.drugbank.com/drugs/DB13434
    Investigational

    Fenticonazole has a broad spectrum of antimycotic activity against dermatophytes and yeasts.[A275048]

    Products: LOMEXIN 600 MG OVULOS, JİNOMED 600 MG OVÜL, 2 OVÜL
  6. Drug

    Vafidemstat

    go.drugbank.com/drugs/DB16446
    Investigational

    Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).

  7. Drug

    Budigalimab

    go.drugbank.com/drugs/DB16668
    Investigational

    With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis). … Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination

  8. Drug

    CMC 001

    go.drugbank.com/drugs/DB05353
    Investigational

    CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.

  9. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  10. Drug

    AV-COVID-19

    go.drugbank.com/drugs/DB15802
    Investigational

    AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF). … As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.